Panoramic Capital LLC purchased a new position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 48,571 shares of the company's stock, valued at approximately $846,000. Panoramic Capital LLC owned 0.08% of Pulse Biosciences as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Tower Research Capital LLC TRC increased its holdings in Pulse Biosciences by 98.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock valued at $29,000 after purchasing an additional 838 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Pulse Biosciences during the 4th quarter worth about $44,000. Caisse Des Depots ET Consignations acquired a new stake in Pulse Biosciences during the 4th quarter worth about $95,000. Farther Finance Advisors LLC grew its holdings in Pulse Biosciences by 44.4% during the 4th quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company's stock worth $126,000 after acquiring an additional 2,220 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in Pulse Biosciences during the 4th quarter worth about $193,000. Institutional investors own 76.95% of the company's stock.
Pulse Biosciences Price Performance
NASDAQ PLSE traded up $0.70 during trading hours on Friday, hitting $17.19. The company's stock had a trading volume of 174,904 shares, compared to its average volume of 197,668. Pulse Biosciences, Inc. has a 52 week low of $7.60 and a 52 week high of $25.00. The company's 50-day simple moving average is $16.57 and its two-hundred day simple moving average is $17.98.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter.
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research report on Monday, March 31st.
Check Out Our Latest Analysis on Pulse Biosciences
About Pulse Biosciences
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
